Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-30 | Abliva | Amended number of shares and votes in Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-30 | Abliva | Ändring av antal aktier och röster i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Abliva | Abliva beslutar om en riktad emission av aktier till garanter i samband med den genomförda företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Abliva | Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Abliva | Abliva AB publicerar årsredovisningen för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Abliva | Abliva AB Publishes 2023 Annual Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Abliva | Kallelse till årsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Abliva | Notice of Annual General Meeting of Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-19 | Abliva | Abliva publishes rights issue outcome | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Abliva publishes rights issue outcomeTHIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER COUNTRY WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 22 February 2024 (the “Rights Issue”), has been completed. In the Rights Issue, 184,931,634 shares, corresponding to approximately 64.2 percent of the Rights Issue, were subscribed for with the use of subscription rights. In addition, 3,241,219 shares, corresponding to approximately 1.1 percent of the Rights Issue, were subscribed for without the use of subscription rights and 99,908,735 shares, corresponding to approximately 34.7 percent of the Rights Issue, were subscribed for by share issue guarantors. In total, the Rights Issue was subscribed to 100 percent, which implies that Abliva raises approximately SEK 46 million before deduction for transactions costs. The rights issue is part of an approximately SEK 88 million financing that also includes a directed issue of convertible bonds to a limited number of certain existing shareholders and institutional investors, provided that the result from the interim analysis, in mid-2024, is positive (non-futile). Through the Rights Issue, Abliva raises approximately SEK 46 million before transactions costs, which are estimated to amount to approximately SEK 6.5 million. The final outcome shows that 184,931,634 shares, corresponding to approximately 64.2 percent of the Rights Issue, were subscribed for with the use of subscription rights. In addition, 3,241,219 shares, corresponding to approximately 1.1 percent of the Rights Issue, were subscribed for without the use of subscription rights and 99,908,735 shares, corresponding to approximately 34.7 percent of the Rights Issue, were subscribed for by share issue guarantors. Through the Rights Issue, the Company’s share capital increases by SEK 14,404,079.40 from SEK 52,814,958.25 to SEK 67,219,037.65 and the number of shares increases by 288,081,588 shares from 1,056,299,165 shares to 1,344,380,753 shares. Trading in paid subscribed shares (BTA) on Nasdaq Stockholm will continue under the short name ABLI BTA until the Rights Issue has been registered with the Swedish Companies Registration Office (Sv. Bolagsverket), which is expected to take place on or around May 8, 2024. After that, BTA will be converted into shares after approximately one week. Allotment of shares subscribed for without the use of subscription rights has been made in accordance with the principles set out in the prospectus that has been prepared for the Rights Issue and published by the Company on 27 March 2024. Notice of allotment is provided through the distribution of a settlement note by mail to the respective subscriber. Allotted shares shall be paid for in accordance with the instructions on the settlement note. “I would like to take this opportunity to thank everyone who participated in the rights issue. Your participation ensures that we can continue our work in the KL1333 program while we carry out the interim analysis. In addition, this financing will allow us to prepare for the final stage of the FALCON study while providing additional runway to discuss the program with potential partners and investors”, said Ellen Donnelly, CEO of Abliva AB. Holders of convertible bonds shall convert the entirety of the loan amount within five banking days from the time at which the Company announces the interim data from the KL1333 Phase 2 study, estimated in mid-2024, if it results in a positive, i.e. non futile, outcome. Advisors |
||||
2024-04-19 | Abliva | Abliva offentliggör utfall i företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-08 | Abliva | BioStock: Abliva vill bli en nyckelspelare inom mitokondriell medicin | Pressreleaser | Visa Stäng |
|
||||
2024-04-08 | Abliva | BioStock: Abliva's mission to become mitochondrial medicine powerhouse | Pressreleaser | Visa Stäng |
|
||||
2024-03-27 | Abliva | Abliva offentliggör prospekt med anledning av företrädesemission som till 100 procent omfattas av tecknings- och garantiåtaganden och upptagande till handel av nyemitterade aktier | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Abliva | Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-26 | Abliva | Beslut vid extra bolagsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-26 | Abliva | Resolutions at the Extraordinary General Meeting in Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Abliva | BioStock: Ablivas vd kommenterar den föreslagna kapitalanskaffningen | Pressreleaser | Visa Stäng |
|
||||
2024-02-29 | Abliva | BioStock: Abliva's CEO comments on the proposed capital raise | Pressreleaser | Visa Stäng |
|
||||
2024-02-27 | Penser Future by Carnegie | Penser Future by Carnegie: Abliva - Interimdata i sommar | Pressreleaser | Visa Stäng |
|
||||
2024-02-23 | Abliva | Abliva AB Year-End Report January – December 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-23 | Abliva | Abliva AB Bokslutskommuniké januari – december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | Notice of Extraordinary General Meeting of Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | Kallelse till extra bolagsstämma i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | Styrelsen för Abliva beslutar om en fullt garanterad företrädesemission om 46 MSEK och en riktad emission av konvertibler om 42 MSEK för att förbereda slutfasen av FALCON-studien med KL1333 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Abliva | The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Abliva | BioStock: Abliva reaches enrollment goal | Pressreleaser | Visa Stäng |
|
||||
2023-12-21 | Abliva | BioStock: Abliva når mål för patientinkludering | Pressreleaser | Visa Stäng |
|
||||
2023-12-20 | Abliva | Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Abliva | Abliva når mål för patientinkludering i Steg 1 av FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-15 | Abliva | BioStock: Ablivas vd: "Orphan drug designation is great validation" | Pressreleaser | Visa Stäng |
|
||||
2023-12-15 | Abliva | BioStock: Abliva's CEO: "Orphan drug designation is great validation" | Pressreleaser | Visa Stäng |
|
||||
2023-12-15 | Penser Future by Carnegie | Penser Future by Carnegie: Abliva - Huvudkonkurrent misslyckas | Pressreleaser | Visa Stäng |
|
||||
2023-12-14 | Penser Future by Carnegie | Penser Future by Carnegie: Abliva - 4 minutes by Penser | Pressreleaser | Visa Stäng |
|
||||
2023-12-14 | Abliva | Abliva erhåller särläkemedelsklassificering från EU-kommissionen för sin läkemedelskandidat NV354 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-14 | Abliva | Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-20 | Penser Future | Penser Future: Luft under vingarna - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-11-17 | Abliva | Abliva AB Delårsrapport januari – september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-17 | Abliva | Abliva AB Interim Report January – September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Abliva | BioStock: Abliva signs global license deal for NeuroSTAT | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Abliva | BioStock: Abliva tecknar globalt licensavtal för NeuroSTAT | Pressreleaser | Visa Stäng |
|
||||
2023-11-15 | Penser Future | Penser Future: Licensierar ut NeuroSTAT - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-11-14 | Abliva | Abliva och Owl Therapeutics ingår licens- och samarbetsavtal för NeuroSTAT® vid traumatisk hjärnskada | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Abliva | Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Abliva | Abliva presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-10-18 | Abliva | BioStock: Abliva's VP of Clinical Operations on the screening achievement | Pressreleaser | Visa Stäng |
|
||||
2023-10-18 | Abliva | BioStock: Ablivas VP of Clinical Operations om uppnått screening-mål | Pressreleaser | Visa Stäng |
|
||||
2023-10-11 | Abliva | Abliva Achieves Important Milestone in the Ongoing FALCON Study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Abliva | Abliva når viktig milstolpe i den pågående FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-19 | Abliva | BioStock:Abliva increases awareness of mitochondrial diseases | Pressreleaser | Visa Stäng |
|
||||
2023-09-19 | Abliva | BioStock:Abliva ökar medvetenheten om mitkondriella sjukdomar | Pressreleaser | Visa Stäng |
|
||||
2023-09-18 | Abliva | Abliva to Participate in World Mitochondrial Disease Week 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-18 | Abliva | Abliva uppmärksammar World Mitochondrial Disease Week 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-08 | Abliva | BioStock: Abliva erhåller FDA Fast Track-status | Pressreleaser | Visa Stäng |
|
||||
2023-09-08 | Abliva | BioStock: Abliva receives FDA Fast Track designation | Pressreleaser | Visa Stäng |
|
||||
2023-09-04 | Abliva | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-04 | Abliva | Ablivas huvudkandidat KL1333 får Fast Track-status från FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | Penser Future | Penser Future: Patientrekrytering i fokus - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-08-18 | Abliva | Abliva AB Delårsrapport januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-18 | Abliva | Abliva AB Interim Report January – June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: First patient dosed in Abliva's Falcon study | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: Första patienten doserad i Ablivas Falcon-studie | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: Första patienten doserad i Ablivas Falcon-studie | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Abliva | BioStock: First patient dosed in Abliva's Falcon study | Pressreleaser | Visa Stäng |
|
||||
2023-06-29 | Abliva | Abliva presenterar på UMDF Mitochondrial Medicine 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Abliva | Abliva presents at UMDF Mitochondrial Medicine 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Abliva | Abliva announces first patient dosed in the FALCON study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Abliva | Abliva meddelar att första patienten doserats i FALCON-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-14 | Abliva | BioStock: Abliva's presence is felt at Euromit | Pressreleaser | Visa Stäng |
|
||||
2023-06-14 | Abliva | BioStock: Ablivas CMO om presentation på Euromit | Pressreleaser | Visa Stäng |
|
||||
2023-06-12 | Abliva | Abliva presents scientific data at international conference on mitochondrial medicine | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Abliva | Abliva presenterar vetenskapliga data vid internationell konferens inom mitokondriell medicin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Penser Future | Penser Future: Tidsplan för FALCON-studien intakt - Abliva | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Penser Future | Penser Future: Interview with Abliva - Erik Penser Bank - May 24th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-23 | Abliva | Abliva AB Interim Report January – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | Abliva | Abliva AB Delårsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Abliva | Beslut vid årsstämma den 5 maj 2023 i Abliva AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Abliva | Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Abliva | Ändring av valberedningens förslag till Ablivas årsstämma 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Abliva | Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|